Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Aspart (NovoLog) vs Insulin Degludec (Tresiba)
An educational, source-based comparison of Insulin Aspart (NovoLog) and Insulin Degludec (Tresiba) — how each peptide works, what it's researched for, and what to know before going deeper.
Recombinant insulin analog with proline→aspartic acid at B28, reducing hexamer stability for rapid absorption and prandial glucose control.
- Prandial coverage
- CSII pump therapy
- Inpatient glycemic management
- • FDA-approved.
- • Hypoglycemia is the principal risk.
Ultra-long-acting basal insulin with >42-hour duration.
Insulin analog with a hexadecanedioic acid side chain at LysB29 that forms soluble multi-hexamers at the injection site, releasing monomers slowly for flat, prolonged action.
- Basal insulin therapy
- Flexible dosing schedules
- Reduced nocturnal hypoglycemia
- • FDA-approved.
- • Steady state reached after ~3 days.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Insulin Aspart (NovoLog) | Aspart vs regular insulin postprandial control | Diabetes Care | 2000 | Better postprandial glucose with similar overall safety. |
| Insulin Degludec (Tresiba) | DEVOTE trial | NEJM | 2017 | Cardiovascular safety vs glargine with lower severe hypoglycemia. |
Side-effect & safety grid
- FDA-approved.
- Hypoglycemia is the principal risk.
- FDA-approved.
- Steady state reached after ~3 days.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Insulin Aspart (NovoLog) vs Insulin Degludec (Tresiba) — Key differences
- Class: Insulin Aspart (NovoLog) is classified as Insulin Analog · Endocrine, while Insulin Degludec (Tresiba) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Aspart (NovoLog) — prandial coverage; Insulin Degludec (Tresiba) — basal insulin therapy.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.
Insulin Aspart (NovoLog) — Frequently Asked Questions
Insulin aspart vs lispro — which has faster onset?+
Standard-formulation insulin aspart (Novolog) and insulin lispro (Humalog) both have an onset of ~10–15 minutes and comparable time-to-peak. Ultra-rapid formulations (faster aspart / Fiasp and lispro-aabc / Lyumjev) have slightly earlier appearance in circulation but similar clinical outcomes on postprandial glucose.